Audentes Therapeutics, Inc. (BOLD Quick QuoteBOLD - Free Report) was a big mover last session, as the company saw its shares rise nearly 15% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company for the company—as the stock is now up 19.19% in the past one-month time frame.

The company has seen a mixed track record when it comes to estimate revisions of one increase and three decrease over the past few weeks, while the Zacks Consensus Estimate for the current quarter hasn’t been in the trend either. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

Audentes Therapeutics currently has a Zacks Rank #3 (Hold) while its Earnings ESP is negative.

Audentes Therapeutics, Inc. Price

Audentes Therapeutics, Inc. Price | Audentes Therapeutics, Inc. Quote

A better-ranked stock in the Medical sector is Akari Therapeutics PLC (AKTX Quick QuoteAKTX - Free Report) , which currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank  stocks here.

Is BOLD going up? Or down? Predict to see what others think: Up or Down.

Zacks Editor-in-Chief Goes ""All In"" on This Stock

Full disclosure, Kevin Matras now has more of his own money in one particular stock than in any other. He believes in its short-term profit potential and also in its prospects to more than double by 2019. Today he reveals and explains his surprising move in a new Special Report.

Download it free >>